VRTX vs GILD
VRTX and GILD side by side — valuation & fundamentals (public data).
Key statistics
| Metric | VRTXVERTEX PHARMACEUTICALS INC / MA | GILDGILEAD SCIENCES, INC. |
|---|---|---|
| Market cap | $121.07B | $161.64B |
| P/E (TTM) | 28.3 | 17.7 |
| P/B | 6.25 | 6.87 |
| P/S | 10.0x | 5.5x |
| Dividend yield | — | 2.48% |
| Revenue | $12.22B(TTM) | $29.74B(TTM) |
| Revenue growth (YoY) | 8.9% | 2.4% |
| Net income | $4.34B(TTM) | $9.22B(TTM) |
| Earnings growth (YoY) | 838.1% | 1672.9% |
| EPS, diluted | $16.85(TTM) | $7.35(TTM) |
| EBIT margin | 34.8% | 34.0% |
| ROE | 20.4% | 36.2% |
| ROIC | 25.4% | 21.6% |
| 1y total return | +3.5% | +18.8% |
Figures from SEC filings · for reference only · not investment advice
Crecimiento de $10,000: VRTX frente a GILD
| Métrica | VRTX | GILD |
|---|---|---|
| Valor final | $60.9K | $20.3K |
| Retorno total | +508.6% | +102.9% |
| CAGR | +19.1% | +7.1% |
| Volatilidad | 33.0% | 25.7% |
| Sharpe | 0.58 | 0.25 |
| Sortino | 0.85 | 0.36 |
| Caída máxima | -41.6% | -36.0% |
Basado en 2600 días de negociación comunes, 2016-03-30 → 2026-07-31 · tasa libre de riesgo 3.83% (bono corto del Tesoro actual, mantenido constante)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)